BioPharma Dive June 17, 2024
One biotech executive called the Supreme Court’s decision a “very important win” for the industry, although new challenges to the FDA’s regulation of the drug could still be forthcoming.
The Supreme Court’s unanimous decision last week to reject a conservative group’s challenge to the Food and Drug Administration’s regulation of the abortion pill mifepristone could help to bolster the agency’s decision-making authority.
In a ruling Thursday, the Supreme Court reversed an appeals court verdict that would have limited access to mifepristone, finding the plaintiffs lacked a legal basis to sue the FDA. Their 9-0 opinion allows changes made by the FDA to the drug’s permitted use to remain in effect, including prescriptions by mail.
Biotechnology leaders had voiced concerns over...
Today's Sponsors
Today's Sponsor